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Cory J. Goracke‑Postle1, Chantel C. Burkitt2, Angela Panoskaltsis‑Mortari3, Michael Ehrhardt3, George L. Wilcox4,
Patrick Graupman2, Michael Partington5 and Frank J. Symons6*

Abstract
Background: The underlying pathogenesis of cerebral palsy (CP) remains poorly understood. The possibility of an
early inflammatory response after acute insult is of increasing interest. Patterns of inflammatory and related biomark‑
ers are emerging as potential early diagnostic markers for understanding the etiologic diversity of CP. Their presence
has been investigated in plasma and umbilical cord blood but not in cerebrospinal fluid (CSF).
Methods: A clinical CP sample was recruited using a single-time point cross-sectional design to collect CSF at pointof-care during a standard-of-care surgical procedure (intrathecal pump implant). Patient demographic and clinical
characteristics were sourced from medical chart audit.
Results: Significant (p ≤ 0.001) associations were found among neuroinflammatory, neuroendocrine, and nocicep‑
tive analytes with association patterns varying by birth status (term, preterm, extremely preterm). When between
birth-group correlations were compared directly, there was a significant difference between preterm and extremely
preterm birth subgroups for the correlation between tumour necrosis factor alpha (TNFα) and substance P.
Conclusion: This investigation shows that CSF can be used to study proteins in CP patients. Differences in intercorrelational patterns among analytes varying by birth status underscores the importance of considering birth status
in relation to possible mechanistic differences as indicated by biomarker signatures. Future work should be oriented
toward prognostic and predictive validity to continue to parse the heterogeneity of CP’s presentation, pathophysiol‑
ogy, and response to treatment.
Keywords: Cerebral palsy, Neuroinflammation, Neuroendocrine, Nociceptive, Biomarkers, CSF, Children
Background
Cerebral palsy (CP) is a neurodevelopmental disorder of
movement, muscle tone or posture caused by an insult to
the developing brain before birth, at birth, or before the
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age of two years. CP is the most common motor disability in childhood, affecting an estimated 500,000 American children and occurring in approximately 2 children
per 1,000 live births. The pathogenesis of CP is not fully
understood. CP risk factors predominantly involve perinatal factors such as anoxia and ischemia and prenatal
factors such as young gestational age, intrauterine viral
infections, and maternal thyroid abnormalities. Intrauterine infection and inflammation are of particular
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interest with both maternal response (chorioamnionitis)
and fetal response (funicitis or elevated interleukin-6 in
fetal plasma) being associated with white matter damage (WMD) and CP [1]. Injury and related inflammatory
processes may persist for considerable periods of time
(years) leading to hypotheses and emerging models of
tertiary-like mechanism of damage including epigenetic
regulation and inflammatory relevant changes [2].
Work investigating infection- and neuroinflammatoryrelated biomarkers related to WMD in neonates has
generated evidence mostly supporting a pathway from
intrauterine infection to placental inflammation then to
systemic fetal circulation and the preterm newborn brain
[3]. The specifics of the infection-inflammation-brain
damage link have been described and documented and
are an active area of investigation [4] particularly given
cautions about what level of inference is or is not supported by high quality evidence [5]. What is less clear,
however, is the robustness of the inference supporting an
infection-inflammation-WMD link with CP as an inevitable outcome. There is some evidence for such a link [6],
but it may be conditioned on whether the infant was born
term or preterm. From a more general perspective, the
emerging viewpoint on the role of neuro-inflammation
as a pathophysiological contributor to CP has created the
possibility of a new therapeutic window through which to
view the condition [7, 8].
Specific findings from prior clinical work specifically investigating inflammatory mediators have demonstrated differential biomarker patterns in umbilical
cord serum from infants stratified by preterm and CP
status [1]. Of the potential inflammation markers that
differed between cases and controls, the markers were
lower (based on medians) in the preterm CP cases relative to controls but were higher, relative to controls, in
the term CP cases. Sampling from a different compartment (plasma) and using a different approach, a study
by Lin et al. (2010) comparing school-age children who
were former preterm births reported higher cytokine
responses (increased tumor necrosis factor-alpha
[TNF-α] plasma levels and greater mRNA levels of tolllike receptor four [TLR4]) among those children with
CP who were preterm relative to controls (children
born preterm with normal development) [9]. Another
study of blood, using a serial approach (i.e., repeated
measures) in over 900 preterm infants, documented
elevated concentration values of myriad inflammatoryrelevant mediators which were associated with different
risk profiles depending on the sampling day [10]. Using
CSF from preterm infants with brain injury, DouglasEscobar and Weiss (2012) documented combinations of
biomarker concentration values that could be used to
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inform clinical decision making [4]. Using blood from a
sample of children with and without CP, Zareen (2020)
[11] found significantly increased levels of erythropoietin at baseline in children with CP compared with children in the comparison group. In response to challenge
(lipopolysaccharide), both groups had appropriate and
comparable response profiles for interleukin-8, vascular
endothelial growth factor (VEGF), TNF-α, and granulocyte–macrophage colony-stimulating factor (GMCSF) levels. The children with CP showed a statistically
significant lipopolysaccharide hypo-responsiveness
profile for interleukin-1a, interleukin-1b, interleukin-2,
and interleukin-6 levels. Collectively, the work to date
consistently shows immune and inflammatory differences in children with CP.
There remain gaps in our knowledge about the specific linkages among various immune and related
mechanisms driving hypothesized persistent inflammatory states in children with CP, and the relation among
the various biomarkers, risk factors, and specific outcomes. The overall generality of the findings to date for
the CP population is limited by two kinds of problems,
namely the relative difficulties in establishing valid preclinical models for this purpose [12] and the extreme
paucity of clinically-relevant biomarker research within
this high-need vulnerable patient group. For example,
the relation among the CSF biomarkers investigated
by Douglas-Escobar and Weiss (2012) and CP as an
outcome was not clear [4]. More biomarker data of a
comparable kind from the same and different compartments across the same and different age groups are
needed. To the best of our knowledge, no comparable
work has investigated inflammatory-relevant molecular biomarkers in CSF from children, adolescents, and
young adults with CP.
The purpose of this preliminary investigation was
exploratory. The design was cross-sectional using a
single time point for specimen collection from a clinical sample. There were two specific aims. The first aim
was to document levels of inflammatory and related
molecules in CSF in a sample primarily of school-age
children with CP. To do so, for detectable analytes,
participants were arrayed along each analyte’s concentration gradient. The second aim was to examine
clinically relevant grouping variables (e.g., CP severity, term/preterm birth) to identify any potentially relevant correlational patterns among the molecules. Our
intent was to extend the work initiated by Kaukola and
Lin (described above) using a clinical sample in which
standard-of-care surgical interventions were leveraged
to gain access to CSF for future hypothesis-generating
research purposes.
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Methods
Protocol approval

This study was approved by the Institutional Review
Board (IRB, #0809M46301) of the University of Minnesota. Written informed consent was obtained from each
participant or legal representative (i.e., parent/guardian).
Participants

This study utilized a single-time point cross-sectional
design. Twenty-eight individuals (82% male) with
CP participated (mean age = 9.74 years, SD = 4.36;
range = 4–23). Specific CP diagnoses included: quadriplegia (n = 17), diplegia (n = 5), and triplegia (n = 5).
Participants were included in the study if they (a) had
cerebral palsy, (b) were between 3–25 years of age, and
(c) were scheduled for initial intrathecal baclofen (ITB)
pump implant. Individuals were excluded if (a) they had
an existing cerebral shunt; or (b) they had compounded
dosing (i.e., opioid adjunctive to baclofen) through their
pump. The participants were already characterized clinically using the Gross Motor Functional Classification
System for Cerebral Palsy (GMFCS) to categorize gross
motor function. The GMFCS is a 5-level classification
system based on self-initiated movement with emphasis
on truncal control and walking. The GMFCS is widely
used clinically and in classifying individuals with CP for
research studies [13].
For the subgroup comparisons, the breakdown of participant demographics was as follows: males (n = 23)
and females (n = 5); non-quadriplegia (n = 11) and quadriplegia (n = 17); Caucasian (n = 26) and other (n = 2);
spastic CP (n = 13) and mixed tone CP (n = 12); term
birth, defined as 37 weeks or later (n = 6), preterm birth,
defined as 28–37 weeks (n = 12) and extremely preterm
birth, defined as less than 28 weeks (n = 9); seizure (n = 6)
and no seizure (n = 16) (Table 1).
CSF collection

Patients were consented in accordance with an approved
IRB protocol. If consent was given, CSF was collected
during a standard-of-care surgical procedure (ITB pump
implant). In all cases, the surgery proceeded as usual until
the spinal catheter had been placed. Then, the neurosurgeon collected 10–20 ml of CSF from the spinal catheter
placed well above the spinal puncture site. This method
avoided contaminating the collected CSF with blood.
Immediately following collection, the CSF was placed
on wet ice (+ 4 °C) and transported to a cold room for
processing, centrifuged at 3000 rpm × 5 min, pipetted
into 100 and 250 µL aliquots, flash frozen in liquid nitrogen and archived at -80 °C. After specimen collection,
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the patient was monitored closely following routine
operative and post-operative procedures. There were no
adverse events.
CSF analyte analysis

CSF was analyzed using conventional biochemical methods based on commercially available enzyme-linked
immunosorbent assay (ELISA) kits and expression levels of each marker were quantified. Specifically, samples
were tested by the Cytokine Reference Laboratory (CRL,
University of Minnesota). This is a CLIA’88-licensed
facility (license #24D0931212). Samples were analyzed
for adrenocorticotropic hormone (ACTH), agoutirelated peptide (AgRP), brain-derived neurotrophic
factor (BDNF), ciliary neurotrophic factor (CNTF),
follicle-stimulating hormone (FSH), growth hormone
(GH), luteinizing hormone (LH), prolactin (PRL), and
thyroid stimulating hormone (TSH) using the “Human
Brain-Derived Protein Panel” on the Luminex platform
and done as a multi-plex (Luminex instrument—Bioplex
100 [Bio-Rad, 1000 Alfred Nobel Drive, Hercules, CA,
94547], Software: bio-plex Manager 4.0). The polystyrene bead set (cat. # HPT-66 K-09) with kit lot number
1757143 was used. Kits/reagents were purchased from
EMD Millipore Corporation, Billerica, MA. Interferon α2
(IFNα2), interleukin-1α (IL-1α), interleukin-1ra (IL-1ra),
interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10
(IL-10), interleukin-12p40 (IL-12p40), interleukin-12p70
(IL-12p70), interferon gamma-induced protein 10 (IP10), monocyte chemotactic protein (MCP-1), macrophage inflammatory protein 1β (MIP1β), regulated on
activation normal T expressed and secreted (RANTES),
and tumor necrosis factorα (TNFα) were analyzed using
the “Cytokine/Chemokine Panel 1” on the Luminex platform and done as a multi-plex (Luminex instrument—
Bioplex 100 [Bio-Rad, 1000 Alfred Nobel Drive, Hercules,
CA, 94547], Software: bio-plex Manager 4.0). The polystyrene bead set (cat. # MPXHCYTO-60 K-14) with kit
lot number 1757142 was used. Kits/reagents were purchased from EMD Millipore Corporation, Billerica, MA.
Dynorphin A, neuropeptide Y, somatostatin, β endorphin, cortisol, neurotensin, orexin A, substance P, melatonin, oxytocin, and melanocyte-stimulating hormone
(α-MSH) were analyzed using the “Human Neuropeptide
Panel” on the Luminex platform and done as a multi-plex
(Luminex instrument—Bioplex 100 Bio-Rad, 1000 Alfred
Nobel Drive, Hercules, CA, 94547], Software: bio-plex
Manager 4.0). The polystyrene bead set (cat. # HNP35 K-08) with kit lot number 1823005 was used. Kits/reagents were purchased from EMD Millipore Corporation,
Billerica, MA.
Samples were assayed according to manufacturer’s
instructions. ELISA employ the quantitative sandwich
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Table 1 Participant health information; M ± SD or n (%)

Male
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Complete sample
(n = 28)

Term birth
(n = 6)

Preterm birth
(n = 12)

Extremely preterm birth
(n = 9)

23 (82.1)

3 (50.0)

11 (91.7)

9 (100)

Ethnicity
Caucasian

26 (92.9)

6 (100.0)

12 (100.0)

8 (88.9)

African American

1 (3.6)

0 (0)

0 (0)

1 (11.1)

Other (not specified)

1 (3.6)

0 (0)

0 (0)

0 (0)

Epilepsy
None

16 (57.1)

3 (50.0)

7 (58.3)

6 (66.7)

History of seizure/diagnosis of epilepsy

6 (21.4)

1 (16.7)

4 (33.3)

1 (11.1)

Questionable seizure activity

3 (10.7)

1 (16.7)

0 (0)

1 (11.1)

Missing

3 (10.7)

1 (16.7)

1 (8.3)

1 (11.1)

CP topography
Hemiplegia

1 (3.6)

0 (0)

1 (8.3)

0 (0)

Diplegia

5 (17.9)

2 (33.3)

3 (25.0)

0 (0)

Triplegia

5 (17.9)

1 (16.7)

0 (0)

4 (44.4)

Quadriplegia

17 (60.7)

3 (50.0)

8 (66.7)

5 (55.6)

GMFCS
Level I

3 (10.7)

0 (0)

3 (25.0)

0 (0)

Level II

3 (10.7)

1 (16.7)

0 (0)

2 (22.2)

Level III

7 (25.0)

3 (50.0)

2 (16.7)

2 (22.2)

Level IV

8 (28.6)

1 (16.7)

4 (33.3)

3 (33.3)
2 (22.2)

Level V

6 (21.4)

1 (16.7)

2 (16.7)

Missing

1 (3.6)

0 (0)

1 (8.3)

Tone
Spastic

13 (46.4)

4 (66.7)

5 (41.7)

4 (44.4)

Mixed tone

12 (42.9)

2 (33.3)

5 (41.7)

4 (44.4)

Missing

3 (10.7)

0 (0)

2 (16.7)

1 (11.1)

Current feeding tube
Yes

8 (28.6)

2 (33.3)

2 (16.7)

4 (44.4)

No

19 (67.9)

4 (66.7)

10 (83.3)

5 (55.5)

Missing
Days in NICU at birth
Range of NICU days

1 (3.6)

0(0)

0 (0)

0 (0)

76.25 ± 67.04
(0–300)

3.50 ± 7.00
(0–14)

52.73 ± 29.72
(10–120)

137.33 ± 64.76
(90–300)

Note: gestational age was not available for one participant; Term birth = born 37 weeks gestation or later; preterm birth = born at 28–37 weeks gestation; extremely
preterm birth = born at less than 28 weeks gestation; CP Cerebral Palsy, GMFCS Gross Motor Function Classification System, level I ambulant without assistance, level
II ambulant without assistive devices, limitations outside the home, level III ambulant with assistive devices, wheelchair required outside the home, level IV nonambulatory, self-mobile in wheelchair with limitations, level V non-ambulatory, self-mobility very limited

enzyme immunoassay technique. The absorbance is
measured on the microtiter plate reader (Bio-Rad model
550). The intensity of the color formed is proportional
to the concentration of the sample. Fluorescent colorcoded beads coated with a specific capture antibody were
added to each sample. After incubation, and washing,
biotinylated detection antibody was added, followed by
phycoerythrin-conjugated streptavidin. The beads were
read on a Luminex instrument (Bioplex 100) which is a
dual-laser fluidics-based instrument. One laser determines the analyte being detected via the color coding; the
other measures the magnitude of the PE signal from the

detection antibody which is proportional to the amount
of analyte bound to the bead. Samples were tested in
duplicate and values were interpolated from 5 parameterfitted (5PL) standard curves.
Statistical analyses

Data analysis was exploratory and relied on visual analysis, descriptive statistics, and correlational analyses. First,
visual analysis of each analyte was conducted to understand its distributional form and to identify potential
outliers. Further, measures of central tendency (means,
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medians) and variation (standard deviations, coefficients
of variation) were calculated for each analyte.
Second, to understand the associations between analytes a series of pairwise scatterplots and Pearson product-moment correlations were computed between each
possible pair of analytes for the entire sample. The correlations were tested for statistical significance against the
null hypothesis of r = 0. Parallel analyses and plots were
generated for the data set with missing data imputed
with the lower limit / sensitivity number. Given the large
number of correlations tested (528), Type 1 errors were
controlled for by using the false discovery rate correction
discussed by Benjamini & Hochberg (1995). Correlations
were considered against an alpha = 0.05, after the false
discovery rate correction was applied.
Third, to understand how the associations between
analytes varied by subgroups, the correlational analyses
described above were repeated for each of the gestational
term subgroups. Given the large number of comparisons involved in these analyses, an alpha = 0.001 was set
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for each test after the false discovery correction rate was
applied.
Finally, differences in correlations between subgroups
were also tested. To be included in between-group
analysis, each correlation first had to be statistically
significant within the subgroups. Thirty-two pairs of
correlations were statistically significant across all subgroups. Then the identified correlations were tested
against one another to check whether they were significantly different by birth status. To do this, Fisher’s
r to z transformation was used to calculate the difference in correlations that met the criteria for inclusion,
and tested for statistical significance of that difference;
p ≤ 0.05.

Results
CSF analyte expression in CP subjects

Detectable CSF analytes were broken down, broadly,
by the following categories: hormonal/endocrine
brain-derived peptides or proteins: ACTH, AgRP,

Fig. 1 Visual representation of the direction and strength of the Pearson’s correlation coefficients between all 33 analytes assayed. Positive (blue),
negative (red), strong (dark shading), and weak (light shading) correlations are depicted
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BDNF, CNTF, FSH, GH, LH, PRL, and TSH; inflammatory cytokines/chemokines: IL-1α, IL-1ra, IL-6,
IL-8, IL-10, IL-12p40, IL-12p70, TNFα, IFN-α2, IP-10,
MCP-1, MIP1β, and RANTES; and neurotransmitters/
neuropeptides: Dynorphin A, neuropeptide Y, somatostatin, β endorphin, cortisol, neurotensin, orexin A,
substance P, melatonin, oxytocin, melanocyte-stimulating hormone (α-MSH). Figure 1 illustrates the
correlations among analytes (at p ≤ 0.001); a full list
of analytes that demonstrated correlations (p ≤ 0.05)
among the participants with CP is included in the Supplemental Information (Supplemental Table 1).
Considering this initial complete cohort, there were
35 analyte pairings with positive correlations as per our
criteria from 21 distinct analytes (all p ≤ 0.001; Table 2).
These 35 correlations represent combinations of endocrine, inflammatory, and excitatory neuropeptides. The
specific correlation pattern represents a novel approach
to considering analytes that may shed light on the mechanistic underpinnings of secondary processes that may
be ongoing in CP and result in clinical signs and their
manifestation.
To assess the potential of such protein signatures in
CSF to distinguish differences relating to biological variables underlying various subpopulations of CP patients,
we assessed analyte correlations between various subgroups. This analysis provided novel information, with
analyte signature correlations becoming apparent for
specific subsets of participant groups. This report
focuses on birth term as a defining characteristic; however, the Supplemental Information provides full analyses of various subgroups based on additional clinical
characteristics.
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Table 2 Significant Pearson’s correlations (p ≤ 0.001) between
analyte pairs, representing 21 distinct analyte correlations (bold
font)
Analyte 1

Analyte 2

Correlation

95% CI

Adj. p

Dynorphin A

AGRP

0.71

[0.34, 0.85]

< .001

Dynorphin A

ACTH

0.79

[0.60, 0.90]

< .001

Dynorphin A

IL-12p70

0.68

[0.41, 0.84]

0.001

Dynorphin A

TNFα

0.80

[0.60, 0.90]

< .001

Dynorphin A

substance P

0.78

[0.57, 0.89]

< .001

AGRP

IL-6

0.73

[0.49, 0.87]

< .001

AGRP

IL-8

0.71

[0.46, 0.86]

< .001

AGRP

IL-10

0.91

[0.81, 0.96]

< .001

AGRP

IL-12p40

0.73

[0.50, 0.87]

< .001

AGRP

MIP-1β

0.94

[0.87, 0.97]

< .001

AGRP

TNFα

0.67

[0.40, 0.84]

0.001

FSH

LH

0.89

[0.78, 0.95]

< .001

TSH

ACTH

0.69

[0.42, 0.84]

0.001
< .001

ACTH

IL-12p70

0.82

[0.65, 0.92]

ACTH

TNFα

0.92

[0.83, 0.96]

< .001

ACTH

β endorphin

0.67

[0.40, 0.83]

0.001

ACTH

substance P

0.91

[0.81, 0.96]

< .001

IFNα2

IL-12p70

0.73

[0.49, 0.87]

< .001

IL-1α

IL-12p40

0.78

[0.57, 0.89]

< .001

IL-1α

IP-10

0.79

[0.60, 0.90]

< .001

IL-1RA

orexin A

0.75

[0.52, 0.88]

< .001

IL-6

IL-10

0.87

[0.74, 0.94]

< .001
0.001

IL-6

IL-12p40

0.68

[0.41, 0.84]

IL-8

MIP-1β

0.73

[0.49, 0.87]

< .001

IL-10

IL-12p40

0.74

[0.51, 0.87]

< .001

IL-10

MIP-1β

0.81

[0.63, 0.91]

< .001

IL-12p40

IP-10

0.81

[0.63, 0.91]

< .001

IL-12p70

TNFα

0.91

[0.81, 0.96]

< .001

IL-12p70

substance P

0.82

[0.64, 0.91]

< .001

Gestational age subgroup analyses
Term birth

TNFα

substance P

0.93

[0.86, 0.97]

< .001

β endorphin

orexin A

0.81

[0.63, 0.91]

< .001

No significant correlations between analytes were detected
at the pre-determined significance level (p ≤ 0.001) used
to report the rest of the subgroup findings. There were,
however, two correlations at p ≤ 0.05 specific to Term
Birth participants (correlations which were not present for
Preterm Birth or Extremely Preterm Birth participants)
specifically between IL-1ra and orexin A and between
orexin A and substance P (identical data for both correlations: Correlation (Corr) = 0.99; 95% Confidence Interval
(CI) = [0.89, 1]; Adjusted P (Adj P) = 0.041) (Fig. 2).

β endorphin

substance P

0.81

[0.62, 0.91]

< .001

β endorphin

αMSH

0.70

[0.44, 0.85]

0.001

orexin A

substance P

0.70

[0.44, 0.85]

0.001

orexin A

αMSH

0.79

[0.58, 0.90]

< .001

Preterm birth

Extremely Preterm Birth status also resulted in distinct
analyte correlations different from both Term Birth and
Preterm Birth participants (Fig. 4). There were 24 discrete analyte correlations unique in this sample of participants in the extremely preterm birth status (bold in
Table 4).

Preterm Birth status resulted in clusters of analytes that
were highly correlated to one another (Fig. 3). There
were 14 discrete correlations not found in the other gestational subgroup (bolded in Table 3); these correlations

represent unique correlations in this sample specific to
individuals born preterm.
Extremely preterm birth
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Fig. 2 Visual representation of the direction and strength of the Pearson’s correlation coefficients between all 33 analytes assayed within the Term
Birth subgroup. Positive (blue), negative (red), strong (dark shading), and weak (light shading) correlations are depicted. *In instances where the
same value was reported for each variable, no correlation was calculated

Between subgroup analyses

Differences in correlations between subgroups were
also directly tested. As noted above, to be included in
between-group analysis, each correlation first had to be
statistically significant within the subgroups. Thirtytwo pairs of correlations were statistically significant
across all subgroups. Then the identified correlations
were tested against one another to check whether they
were significantly different by birth status. Based on this
approach, there was a significant difference between the
Preterm and Extremely Preterm Birth subgroups for the
correlation between TNFα and substance P (Extremely
Preterm r to z = 0.99, Preterm r to z = 0.82, Z Difference = 1.49, p < 0.05).

Discussion
There are many different ways that white matter and
upper motor neurons can be damaged. It is generally agreed that enough damage will interfere with and

ultimately impair motor control and increase risk for the
clinical condition of CP (importantly there are, of course,
other associated impairments including cognitive and
sensory function). Of the many putative causal agents
and pathways to CP, the role of neuroinflammation in
perinatal brain damage has received considerable empirical attention. There has also been considerable conceptual emphasis challenging conventional wisdom about
the nature of the threat in relation to inflammation and
the developing brain with a distinct shift to a perspective
that a core underlying feature may be less about static
events (i.e., a one-time insult) and more about sustained
states (i.e., an ongoing process). The significance of this
shift is in widening the focus of inquiry to include tertiary
mechanisms of brain damage, which, in turn, could shed
new light on a very old problem – namely treating CP
based on its underlying pathophysiology.
There is a working hypothesis that suggests that the
relationship among key neuroendocrine hormones,
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Fig. 3 Visual representation of the direction and strength of the Pearson’s correlation coefficients between all 33 analytes assayed within the
Preterm Birth subgroup. Positive (blue), negative (red), strong (dark shading), and weak (light shading) correlations are depicted

excitatory neuropeptides, and neuroinflammatory
cytokines as markers may be a critical variable predicting outcome. The conceptual basis for this is the past
two decades of work supporting the cross-talk among
the endocrine, nociceptive, and immune systems. In
healthy states there is an optimal balance between stress
hormones and proinflammatory cytokines. In children
with CP, the white matter damage may be ‘driving’ an
immune-mediated inflammatory cascade. There is evidence supporting this possibility from three related studies with CP patients, one using umbilical cord serum [1],
one using plasma [9], and one using blood [11].
The current analysis expands the previous work and
provides further description of the molecular milieu present in the CNS of CP patients. Such documentation provides a unique opportunity to consider how differences
in CNS concentrations of various inflammatory-relevant
analytes between differing presentations of CP may be
relevant for hypotheses about mechanisms underlying the differential outcomes in CP. Specifically, in this

sample, it was observed that Term Birth, Preterm Birth,
and Extremely Preterm Birth status was associated with
distinct patterns of analyte inter-correlations. If reproducibility of these findings could be established, there
is an opportunity to better understand the mechanisms
underlying various and varying outcomes specific to
birth term in CP.
The correlations present in the participants suggest
relationships among systems subserving arousal (orexin
A), inflammation (TNFα), anti-inflammation (IL-1ra),
and neuronal excitation (substance P), with distinctions
depending on birth term. Orexin A (hypocretin 1) is an
excitatory, hypothalamic neuropeptide that binds to
both the orexin 1 and 2 receptors (OX1R and OX2R); the
former is thought to act largely through the excitatory
Gq protein and both are implicated in wakefulness and
sleep cycle stability [14]. Narcoleptic symptoms in dogs
and mice are associated with loss-of-function mutations
in the gene encoding OX2R, although immunosuppression can delay symptom onset, and deletion of the gene
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Table 3 Significant Pearson’s correlations (p ≤ 0.001) between
analyte pairs in the Preterm Birth subgroup are displayed. There
were 14 unique positive analyte correlations (bold font) specific
to the Preterm Birth subgroup that were not significant within
the other gestational age subgroups
Analyte 1

Analyte 2

Correlation

95% CI

Adj. p

AGRP

IL-1ra

0.93

[0.75, 0.98]

0.001

AGRP

IL-10

0.93

[0.75, 0.98]

0.001

IL-12.p40

IP-10

0.91

[0.70, 0.97]

0.001

IL-12.p70

substance P

0.92

[0.73, 0.98]

0.001

AGRP

LH

0.93

[0.77, 0.98]

< .001

LH

IL-1ra

0.94

[0.80, 0.98]

< .001

LH

IL-10

0.94

[0.80, 0.98]

< .001

LH

MIP-1β

0.94

[0.79, 0.98]

< .001

IL-1ra

IL-10

1.00

[1.00, 1.00]

< .001

IL-1ra

MIP-1β

0.97

[0.90, 0.99]

< .001

IL-10

MIP-1β

0.97

[0.90, 0.99]

< .001

IL-12.p70

TNFα

0.93

[0.78, 0.98]

< .001

RANTES

β endorphin

0.97

[0.89, 0.99]

< .001

RANTES

Melatonin

0.95

[0.81, 0.99]

< .001

β endorphin

Melatonin

0.99

[0.97, 1.00]

< .001

encoding both orexins in mice results in a full narcolepsy
phenotype [14]. Substance P is another excitatory neuropeptide that binds to neurokinin 1 receptors (NK1R),
which couple through the excitatory Gq protein. Substance P is contained in and released by some C-fiber
nociceptors and causes activation and internalization
of NK1Rs on nociceptive spinal cord neurons, exciting
them [15]. These neurons project to the thalamus carrying information on the sensory-discriminative aspects of
pain ultimately to the somatosensory cortex [16]. Thus,
Substance P is thought to be one of the important drivers of pain transmission in spinal cord and trigeminal
nucleus. IL-1ra is an endogenous anti-inflammatory
cytokine that binds unproductively to the IL-1 receptor 1 (IL1R1), thereby blocking signaling by two proinflammatory cytokines IL-1α and IL-1β. The FDA has
approved an altered form of human IL-1ra in the form
of anakinra for use in peripheral inflammatory disorders
like rheumatoid arthritis [17]. In the CNS, both of these
cytokines, acting through IL1R1s on astrocytes, endothelial cells, and neurons, initiate transcription of multiple
pro-inflammatory cytokines, including TNFα, leading to
reactive gliosis and enhanced neuronal excitability following such insults as traumatic brain injury.
In clinical investigations, evidence suggests an autoimmune destruction of orexin neurons [14], and orexin
A and IL-1ra in CSF have been associated with fatigue
in Sjögren’s syndrome [18]. At least one study found

decreased levels of substance P in the CSF of patients
with narcolepsy [19], a disorder for which orexin A deficiency is a well-known biomarker [20]. Sleep dysfunction is well-established in CP; our observations suggest
that specific inflammatory and nociceptive mediators
may be implicated and future work should be designed
to investigate in more detail the relation between sleep,
inflammation, and neuronal excitation in CP based on
biomarker-informed molecular signatures that may be
specific to birth status.
Further, the relevance of the difference between the
Preterm and Extremely Preterm subgroups appears
particularly striking and significant given the literature documenting the clinical differences in phenotypic
presentation between these two groups. Understanding
the relationship between TNFα and substance P expression and regulation may have implications related to the
underlying pathophysiology with possible prognostic and
treatment relevance. One study of cultured human astrocytes demonstrated a functional interaction between
these two analytes: substance P enhanced the stimulatory effect of TNFα on production of two inflammatory
mediators: IL-6 and P
 GE2 [21]. This birth term-associated analyte difference may underscore the importance of
our observed positive correlation to a functional interaction between a nociceptive neurotransmitter, substance
P, and a pro-inflammatory cytokine, TNFα, as one of the
inflammatory processes perhaps underlying the development and/or presentation of CP.
From a knowledge translation perspective, the correlation difference between Preterm and Extremely Preterm
Birth subgroups for TNFα and substance P may represent
a potential interaction and intervention point between
inflammation and nociceptive neurotransmission specifically in the CNS; however, demonstration of a spinal
or trigeminal localization of this interaction would be
required to underpin this interpretation. Such an understanding may provide an opportunity to improve outcomes through earlier intervention that includes targeting
these specific pathways and their unique mechanisms.
One weakness of the current analysis is that the group
sizes are not robust enough to distinguish larger signature patterns/differences between groups that may be
informational for identifying distinctions between different patient subgroup populations; ultimately, there may
be different CP patient subgroups with specific, identifiable protein signatures. Larger samples with confirmatory
analyses are needed. Additionally, further consideration
regarding appropriate comparison groups or control
samples is warranted. Healthy controls could be useful
(see below regarding a point about establishing normative values) but their use could be limited in so much
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Fig. 4 Visual representation of the direction and strength of the Pearson’s correlation coefficients between all 33 analytes assayed within the
Extremely Preterm subgroup. Positive (blue), negative (red), strong (dark shading), and weak (light shading) correlations are depicted. *In instances
where the same value was reported for each variable, no correlation was calculated

as it might be more important to consider inclusion of
carefully defined samples from other neurodegenerative
disorders in which more is known about the underlying
immune pathology and disease progression (e.g., multiple
sclerosis). Doing so would provide important points of
comparison for similarities and differences in inflammatory analyte levels/profiles that would, in turn, increase
our understanding of inflammatory mechanisms specific
to the CP phenotype.
Our long-term goal is to establish clinical value in
adopting a biomarker approach to understand clinical
outcomes among patients with CP. A biological marker
or biomarker is any characteristic that can be measured
and evaluated as an indicator of normal biologic processes, pathologic processes, or pharmacologic responses
to therapeutic intervention. Biomarkers hold the potential of a better understanding of the etiology and pathology of a given disorder, providing valuable insight into
diagnosis, treatment, and prognosis for many debilitating

disorders and diseases. Current diagnostic and therapeutic approaches to manage chronic disability among individuals with neurodevelopmental disorders including CP
are limited by our narrow understanding of the biological
mechanisms underlying developmental disorders of various etiologies and confounded further by phenotypic and
etiologic heterogeneity (e.g., there is not one cause of CP;
clinical presentation varies widely) and the lack of biomarkers predictive of therapeutic outcome.
Part of the hope is that molecular biomarkers may provide a useful ‘work around’ for closing the gap between
clinical presentation and often unknown underlying
pathophysiology in CP. To get there, however, there are
enormous gaps in what is known from a normative perspective within the population of CP (e.g., there are few
to no referent values for expected concentration values
of the vast majority of inflammatory mediators). The
difficulty with any clinical sample is whether the detectable analyte represents a biomarker for ‘exposure’ (to
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Table 4 Significant Pearson’s correlations (p ≤ 0.001) between
analyte pairs in the Extremely Preterm Birth subgroup. There
were 24 unique positive analyte correlations (bold font)
specific to the Extremely Preterm Birth subgroup that were not
significant within the other gestational age subgroups
Analyte 1

Analyte 2

Correlation

95% CI

Adj. p

AGRP

IL-6

0.96

[0.83, 0.99]

0.001

AGRP

IP-10

0.96

[0.81, 0.99]

0.001

AGRP

MIP-1β

0.95

[0.79, 0.99]

0.001

ACTH

β endorphin

0.96

[0.81, 0.99]

0.001

IP-10

MIP-1β

0.96

[0.80, 0.99]

0.001

TNFα

β endorphin

0.96

[0.81, 0.99]

0.001

AGRP

IL-1α

0.98

[0.92, 1.00]

< .001

AGRP

IL-10

0.98

[0.92, 1.00]

< .001

AGRP

RANTES

0.99

[0.95, 1.00]

< .001

AGRP

Oxytocin

0.98

[0.92, 1.00]

< .001

TSH

Prolactin

0.97

[0.86, 0.99]

< .001

ACTH

TNFα

0.98

[0.92, 1.00]

< .001

ACTH

substance P

0.97

[0.88, 0.99]

< .001

IL-1α

IL-6

0.98

[0.92, 1.00]

< .001

IL-1α

IL-10

1.00

[1.00, 1.00]

< .001

IL-1α

RANTES

0.99

[0.96, 1.00]

< .001

IL-1α

Oxytocin

1.00

[1.00, 1.00]

< .001

IL-6

IL-10

0.98

[0.92, 1.00]

< .001

IL-6

RANTES

0.97

[0.87, 0.99]

< .001

IL-6

Oxytocin

0.98

[0.92, 1.00]

< .001

IL-10

RANTES

0.99

[0.96, 1.00]

< .001

IL-10

Oxytocin

1.00

[1.00, 1.00]

< .001

IL-12.p70

β endorphin

0.98

[0.92, 1.00]

< .001

RANTES

Oxytocin

0.99

[0.96, 1.00]

< .001

TNFα

substance P

0.99

[0.97, 1.00]

< .001

an inflammatory process) or ‘outcome’ (of brain damage). There is no easy solution to this dilemma absent an
experimental model. With that point acknowledged, we
believe there is value in continuing to adopt and adapt a
‘biomarker epidemiological’ perspective as outlined by
Dammann [5]. Doing so may help facilitate the development, testing, and application of immunomodulatory
therapies for CP (see Fleiss and Gressens [8] for general
considerations on this and related topics specific to tertiary management of brain damage as well as Lee et al.
2012 [22]).
In particular, it would be important to obtain comparison values from healthy and/or non-inflammatory based
controls to establish the utility of neurochemical profile
patterns as prognostic (natural history-like outcomes)
or predictive tools (what profile would be most responsive to immune modulatory therapy trial). With that said,
as noted above, careful selection of other well-defined

diseases in which immune-mediated inflammation is a
core feature would also be a valuable approach (e.g., multiple sclerosis – for which stem cell treatment trials are
underway with a particular focus on patients with persistent inflammation [23]). A third approach – in a sense
the strategy used for this preliminary work – is sampling
within group (patient), but it would be strengthened considerably by larger samples and if/when ethically feasible, repeated measurement. Such a repeated measures
approach was used by Koh et al. [24] in their investigation of cytokine changes in children with CP receiving
intravenous granulocyte-colony stimulating factor followed by autologous mobilized peripheral blood mononuclear cells.

Conclusion
Given the preliminary data presented here: 1) that
endocrine, neuropeptide, and inflammatory markers
are detectable in CSF from pediatric patients with CP
and 2) that significant correlations exist among markers for endocrine hormones, nociceptive neuropeptides
and inflammatory mediators that are distinct in various
subgroups of individuals with CP, we think it is critical
to continue this line of research to consider further the
functional consequences of altered inflammatory processes and responses in children with CP and to consider
the potential for mechanism-driven intervention based
on protein/peptide/neurotransmitter signatures in CP
patients. Increasing our scientific understanding of the
neurochemical milieu involved in distinct subgroups of
CP may shed light on potential targets for earlier intervention to perhaps prevent transition to more severe
presentation. Clarifying a mechanistic understanding of
developmental differences may be what the analyte patterns are pointing to and offer a specific starting domain
for further exploration. Our hope is that these preliminary findings lay the groundwork for additional studies
to confirm and expand on the potential for protein signatures in CP to be valuable clinical tools in the future.
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Additional file 1: Table 1. A Pearson’s correlation test against the null
hypothesis of 0 was conducted for all possible pairs of analytes assayed,
controlling for familywise Type I errors using the Benjamini & Hochberg
(1995) false discovery rate correction. As there were 528 correlation tests,
only those retaining a significant correlation (p ≤ 0.05) after the false
discovery rate correction are presented. Table 2. Pearson’s correlation
coefficients between pairs of analytes within the Term Birth gestational
age subgroup. Only significant correlations (p ≤ 0.05) after controlling for
false discovery rate are presented. There were no unique analyte correla‑
tions specific to those with Term Birth that were not also significant within
the other gestational age subgroups. Table 3. Pearson’s correlation coef‑
ficients between pairs of anlytes within the Preterm Birth gestational age
subgroup. Only significant correlations (p ≤ 0.05) after controlling for false
discovery rate are presented. Table 4. Pearson’s correlation coefficients
between pairs of analytes within the Extremely Preterm Birth gestational
age subgroup. Only significant correlations (p ≤ 0.05) after controlling for
false discovery rate are presented. Figure 1. Visual representation of the
direction and strength of the Pearson’s correlation coefficients between
analytes assayed within the subgroup with spastic CP. Positive (blue),
negative (red), strong (dark shading), and weak (light shading) correla‑
tions are depicted. Table 5A. Pearson’s correlation coefficients between
pairs of analytes within the subgroup with spastic CP. Complete dataset
of significant correlations (p ≤ 0.05) after controlling for false discovery
rate are presented. Table 5B. Significant Pearson’s correlations (p ≤ 0.001)
between analyte pairs in the subgroup with spastic CP. There were 8
unique positive analyte correlations (bold font) specific to spastic CP that
were not significant within the subgroup with mixed tone CP. Figure 2.
Visual representation of the direction and strength of the Pearson’s cor‑
relation coefficients between analytes assayed within the subgroup with
mixed tone CP. Positive (blue), negative (red), strong (dark shading), and
weak (light shading) correlations are depicted. Table 6A. Pearson’s cor‑
relation coefficients between pairs of analytes within the subgroup with
mixed tone CP. Complete dataset of significant correlations (p ≤ 0.05) after
controlling for false discovery rate are presented. Table 6B. Significant
Pearson’s correlations (p ≤ 0.001) between analyte pairs in the subgroup
with mixed tone CP. There were 7 unique positive analyte correlations
(bold font) specific to mixed tone CP that were not significant within the
subgroup with spastic CP. Figure 3. Visual representation of the direction
and strength of the Pearson’s correlation coefficients between analytes
assayed within the subgroup with seizures present. Positive (blue), nega‑
tive (red), strong (dark shading), and weak (light shading) correlations are
depicted. Table 7A. Pearson’s correlation coefficients between pairs of
analytes within the subgroup with seizures present. Complete dataset of
significant correlations (p ≤ 0.05) after controlling for false discovery rate
are presented. Table 7B. Significant Pearson’s correlations (p ≤ 0.001)
between analyte pairs in the subgroup with seizures. There were no
unique analyte correlations specific to those with seizures that were not
also significant within the subgroup without seizures. Figure 4. Visual
representation of the direction and strength of the Pearson’s correlation
coefficients between analytes assayed within the subgroup without sei‑
zures. Positive (blue), negative (red), strong (dark shading), and weak (light
shading) correlations are depicted. Table 8A. Pearson’s correlation coef‑
ficients between pairs of analytes within the subgroup without seizures.
Complete dataset of significant correlations (p ≤ 0.05) after controlling for
false discovery rate are presented. Table 8B. Significant Pearson’s correla‑
tions (p ≤ 0.001) between analyte pairs in the subgroup without seizures.
There were 30 unique positive analyte correlations (bold font) specific to
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those without seizures that were not significant within the subgroup with
seizures. Figure 5. Visual representation of the direction and strength of
the Pearson’s correlation coefficients between analytes assayed within the
subgroup with quadriplegia. Positive (blue), negative (red), strong (dark
shading), and weak (light shading) correlations are depicted. Table 9A.
Pearson’s correlation coefficients between pairs of analytes within the
subgroup with quadriplegia. Complete dataset of significant correlations
(p ≤ 0.05) after controlling for false discovery rate are presented. Table 9B.
Significant Pearson’s correlations (p ≤ 0.001) between analyte pairs in
the subgroup with quadriplegia. There were 16 unique positive analyte
correlations (bold font) specific to those with quadriplegia that were not
significant within the subgroup without quadriplegia. Figure 6. Visual
representation of the direction and strength of the Pearson’s correlation
coefficients between analytes assayed within the subgroup without quad‑
riplegia. Positive (blue), negative (red), strong (dark shading), and weak
(light shading) correlations are depicted. Table 10A. Pearson’s correla‑
tion coefficients between pairs of analytes within the subgroup without
quadriplegia. Complete dataset of significant correlations (p ≤ 0.05) after
controlling for false discovery rate are presented. Table 10B. Significant
Pearson’s correlations (p ≤ 0.001) between analyte pairs in the subgroup
without quadriplegia. There were 2 unique positive analyte correlations
(bold font) specific to those without quadriplegia that were not significant
within the subgroup with quadriplegia.
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